Incyte Current Ratio 2010-2024 | INCY

Incyte current ratio for the quarter ending June 30, 2024 was 1.92.

  • Incyte average current ratio for 2023 was 3.86, a 3.21% decline from 2022.
  • Incyte average current ratio for 2022 was 3.74, a 3.36% increase from 2021.
  • Incyte average current ratio for 2021 was 3.87, a 7.2% decline from 2020.

Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.

Incyte Current Ratio 2010-2024 | INCY

  • Incyte average current ratio for 2023 was 3.86, a 3.21% decline from 2022.
  • Incyte average current ratio for 2022 was 3.74, a 3.36% increase from 2021.
  • Incyte average current ratio for 2021 was 3.87, a 7.2% decline from 2020.

Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$180.5B
Regeneron Pharmaceuticals (REGN)$126.8B
Vertex Pharmaceuticals (VRTX)$123.3B
Gilead Sciences (GILD)$104.5B
Bristol Myers Squibb (BMY)$99.4B
CSL (CSLLY)$97.5B
GSK (GSK)$86.3B
Alnylam Pharmaceuticals (ALNY)$35.5B
Argenex SE (ARGX)$32.1B
Biogen (BIIB)$29.3B
BioNTech SE (BNTX)$26.8B
Moderna (MRNA)$26.1B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$19.3B
Genmab (GMAB)$17.5B
BioMarin Pharmaceutical (BMRN)$13.6B
Exact Sciences (EXAS)$13.1B
Vaxcyte (PCVX)$13.1B
Insmed (INSM)$12.9B
Bio-Techne Corp (TECH)$12.7B
Sarepta Therapeutics (SRPT)$12.1B
QIAGEN (QGEN)$10.4B
Legend Biotech (LEGN)$9.3B
Bio-Rad Laboratories (BIO.B)$9.1B
Ascendis Pharma (ASND)$8.9B
Roivant Sciences (ROIV)$8.8B
Repligen (RGEN)$8.2B
Intra-Cellular Therapies (ITCI)$8.1B
Exelixis (EXEL)$7.7B
Viking Therapeutics (VKTX)$7.6B